Enanta Pharmaceuticals, Inc. (ENTA): Price and Financial Metrics

Enanta Pharmaceuticals, Inc. (ENTA): $12.06

0.07 (-0.58%)

POWR Rating

Component Grades








Add ENTA to Watchlist
Sign Up

Industry: Biotech




#105 of 362

in industry

ENTA Price/Volume Stats

Current price $12.06 52-week high $28.25
Prev. close $12.13 52-week low $8.08
Day low $11.80 Volume 52,670
Day high $12.21 Avg. volume 234,200
50-day MA $14.43 Dividend yield N/A
200-day MA $12.40 Market Cap 255.42M

ENTA Stock Price Chart Interactive Chart >

Enanta Pharmaceuticals, Inc. (ENTA) Company Bio

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The company was founded in 1995 and is based in Watertown, Massachusetts.

ENTA Latest News Stream

Event/Time News Detail
Loading, please wait...

ENTA Latest Social Stream

Loading social stream, please wait...

View Full ENTA Social Stream

Latest ENTA News From Around the Web

Below are the latest news stories about ENANTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENTA as an investment opportunity.

The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World

Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World are included in this Analyst Blog.

Yahoo | December 20, 2023

Insider Sell Alert: Director Terry Vance Sells 15,295 Shares of Enanta Pharmaceuticals Inc (ENTA)

In a notable insider transaction, Director Terry Vance has parted with 15,295 shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA), a significant move that warrants a closer look by investors and market analysts.

Yahoo | December 16, 2023

Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 108.1% in Enanta Pharmaceuticals (ENTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 13, 2023

How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%

The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 27, 2023

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

WATERTOWN, Mass., November 22, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023 at 7:55 a.m. ET in Miami, FL.

Yahoo | November 22, 2023

Read More 'ENTA' Stories Here

ENTA Price Returns

1-mo -9.46%
3-mo -5.71%
6-mo 34.15%
1-year -54.51%
3-year -75.67%
5-year -87.09%
YTD 28.16%
2023 -79.77%
2022 -37.79%
2021 77.62%
2020 -31.85%
2019 -12.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!